These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27560010)

  • 1. Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid for Quantitative Assessment of Vascular Effects on Hepatocellular-Carcinoma Lesions Treated by Transarterial Chemoembolization or Radiofrequency Ablation.
    Ippolito D; Trattenero C; Talei Franzesi C; Casiraghi A; Lombardi S; Vacirca F; Corso R; Sironi S
    J Comput Assist Tomogr; 2016; 40(5):692-700. PubMed ID: 27560010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients.
    Ippolito D; Fior D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S
    Eur J Radiol; 2014 Sep; 83(9):1665-71. PubMed ID: 24962900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
    Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: How to Pursue Periprocedural Cross-Sectional Imaging?
    Ruff C; Grözinger G; Syha R; Elser S; Partovi S; Bitzer M; Horger M; Nikolaou K; Grosse U
    J Vasc Interv Radiol; 2019 Mar; 30(3):380-389.e4. PubMed ID: 30819480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
    Kamel IR; Bluemke DA; Eng J; Liapi E; Messersmith W; Reyes DK; Geschwind JF
    J Vasc Interv Radiol; 2006 Mar; 17(3):505-12. PubMed ID: 16567675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viable hepatocellular carcinoma around retained iodized oil after transarterial chemoembolization: radiofrequency ablation of viable tumor plus retained iodized oil versus viable tumor alone.
    Kim JH; Kim PN; Won HJ; Shin YM
    AJR Am J Roentgenol; 2014 Nov; 203(5):1127-31. PubMed ID: 25341154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Otto G; Biesterfeld S; Oberholzer K; Dueber C; Pitton MB
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):532-40. PubMed ID: 19847482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization.
    Castrucci M; Sironi S; De Cobelli F; Salvioni M; Del Maschio A
    Abdom Imaging; 1996; 21(6):488-94. PubMed ID: 8875869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of magnetic resonance in the follow-up o hepatocarcinoma treated with percutaneous ethanol injection (PEI) or transarterial chemoembolization (TACE)].
    De Cobelli F; Castrucci M; Sironi S; Livraghi T; Venturini M; Salvioni M; Del Maschio A
    Radiol Med; 1994 Dec; 88(6):806-17. PubMed ID: 7878241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
    Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
    Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study.
    Cho YZ; Park SY; Choi EH; Baik SK; Kwon SO; Kim YJ; Cha SH; Kim MY
    Clin Mol Hepatol; 2015 Jun; 21(2):165-74. PubMed ID: 26157754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study.
    Haochen W; Jian W; Li S; Tianshi L; Xiaoqiang T; Yinghua Z
    J Int Med Res; 2018 Jul; 46(7):2650-2657. PubMed ID: 29683022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenchymal Blood Volume Assessed by C-Arm-Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma.
    Syha R; Grözinger G; Grosse U; Maurer M; Zender L; Horger M; Nikolaou K; Ketelsen D
    Invest Radiol; 2016 Feb; 51(2):121-6. PubMed ID: 26488373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
    Liu HF; Xu YS; Liu Z; Che KY; Sheng Y; Ding JL; Zhang JG; Lei JQ; Xing W
    Acad Radiol; 2021 Jun; 28(6):790-798. PubMed ID: 32414638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.
    Frericks BB; Loddenkemper C; Huppertz A; Valdeig S; Stroux A; Seja M; Wolf KJ; Albrecht T
    AJR Am J Roentgenol; 2009 Oct; 193(4):1053-60. PubMed ID: 19770329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of therapeutic effectiveness of transarterial chemoembolization for hepatocellular carcinoma: correlation of dynamic susceptibility contrast-enhanced echoplanar imaging and hepatic angiography.
    Tsui EY; Chan JH; Cheung YK; Cheung CC; Tsui WC; Szeto ML; Lau KW; Yuen MK; Luk SH
    Clin Imaging; 2000; 24(4):210-6. PubMed ID: 11274885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma.
    El-Kady NM; Esmat G; Mahmoud EH; Darweesh SK; Mahmoud SH; Elagawy WA
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):628-33. PubMed ID: 23325283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viable residual tumor tissue after radiofrequency ablation treatment in hepatocellular carcinoma: evaluation with CT perfusion.
    Ippolito D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S
    Abdom Imaging; 2013 Jun; 38(3):502-10. PubMed ID: 22743839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.